Unjha Formulations Limited has announced its unaudited financial results for the quarter and nine months ended December 31, 2025, showing revenue growth and sustained profitability across both periods. The results were approved by the company's Board of Directors during their meeting held on February 4, 2026.

Quarterly Performance Analysis

The company's Q3FY26 performance demonstrated solid growth compared to the corresponding period in the previous year. Net sales increased significantly, while the company maintained operational efficiency despite higher material costs.

Nine-Month Financial Performance

For the nine-month period ended December 31, 2025, Unjha Formulations showed strong year-over-year growth across key financial metrics. The company's revenue expansion was accompanied by improved profitability margins.

Cost Structure and Operational Efficiency

The company's cost analysis reveals varying trends across different expense categories. Material costs constituted the largest component of expenditure, while employee benefit expenses showed notable increases during the quarter.

Key Cost Components for Q3FY26:

• Cost of materials consumed: ₹338.50 lacs (80.60% of total expenditure)
• Employee benefit expenses: ₹32.09 lacs
• Other expenses: ₹45.08 lacs
• Depreciation and amortization: ₹4.09 lacs
• Finance costs: ₹0.17 lacs

Sequential Quarter Comparison

Comparing Q3FY26 with the previous quarter (Q2FY26), the company showed mixed performance with revenue growth but lower profitability due to increased material and employee costs.

Corporate Governance and Compliance

The financial results were reviewed and approved by the company's Audit Committee and Board of Directors. The limited review was conducted by Jain & Golechha, Chartered Accountants, in accordance with Standard on Review Engagement (SRE) 2410. The company maintains a paid-up equity share capital of ₹448.05 lacs with a face value of ₹10 per share. No investor complaints were pending at the beginning or end of the quarter, reflecting strong corporate governance practices.

Unjha Formulations Limited , a pharmaceutical company, has reported a significant turnaround in its financial performance for the second quarter, despite a slight decline in revenue. The company's board of directors approved the unaudited financial results for the quarter and half-year ended September 30, at a meeting held on November 10.

Q2 Performance Highlights

Unjha Formulations has demonstrated a remarkable improvement in its profitability for the quarter ended September 30. The company reported a profit of Rs 81.78 lacs, a substantial increase from the profit of Rs 38.99 lacs in the previous quarter and a significant turnaround from the loss of Rs 11.06 lacs in the same quarter of the previous year.

Revenue Growth and Cost Management

The company's net sales for Q2 stood at Rs 428.53 lacs, showing an increase of 18.57% compared to the previous quarter and 13.31% year-on-year. This growth in revenue, coupled with effective cost management, has contributed to the improved bottom line.

Total expenditure for the quarter was Rs 352.96 lacs, an increase of 8.80% from the previous quarter but a decrease of 9.90% compared to the same period last year. This indicates that the company has been successful in controlling its costs while growing its revenue.

Half-Year Performance

For the half-year ended September 30, Unjha Formulations reported:

• Net sales of Rs 789.94 lacs, up from Rs 773.40 lacs in the same period last year
• Total income of Rs 798.15 lacs, compared to Rs 776.08 lacs in H1 of the previous year
• A profit of Rs 120.78 lacs, more than doubling from Rs 58.82 lacs in the previous year's first half

Balance Sheet Highlights

As of September 30, the company's financial position shows:

• Total assets of Rs 645.15 lacs, up from Rs 455.65 lacs at the end of the previous fiscal year
• Equity share capital remained unchanged at Rs 448.05 lacs
• Cash and cash equivalents increased to Rs 160.08 lacs from Rs 64.38 lacs

Outlook

While the company has shown impressive growth in profitability, investors should note that these are unaudited results. The sustainability of this growth trend and the company's ability to maintain profitability in the face of potential market challenges will be key factors to watch in the coming quarters.

Unjha Formulations Limited continues to operate in a single business segment. The company reported no pending investor complaints at the beginning or end of the quarter, indicating good investor relations management.

As the pharmaceutical sector remains crucial in the current global health context, Unjha Formulations' performance may be of interest to investors looking at mid-cap pharma companies in the Indian market.